ARX · ASX

Aroa Biosurgery Ltd (ASX:ARX)

AU$0.45

 0.01 (2.273%)
ASX:Live
01/05/2025 12:10:26 PM
HALO Ords HALO Balance Sheet GROWTH AUS Consensus Cheap All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ARX Overview

ARX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Strong

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Strong

Balance Sheet

Very Weak

About ARX

Website

Aroa Biosurgery Ltd

Telephone

64.9.869.3035

Address

64 Richard Pearse Drive Mangere, Auckland 2022

Description

Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. It focuses on healing for complex wounds, and soft tissue reconstruction procedures including abdominal wall reconstruction, breast reconstruction, and reconstructive surgery for trauma, limb salvage, and tumor resections. The company was founded by Brian Roderick Ward in 2008 and is headquartered in Mangere, New Zealand.

ARX Price Chart

Key Stats

Market Cap

AU$151.76M

PE

673.00

EV/EBITDA

71.8

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.35 - 0.81

Trade Value (12mth)

US$44,848.00

1 week

12.82%

1 month

4.76%

YTD

-40.94%

1 year

-12%

All time high

1.75

Key Fundamentals

EPS 3 yr Growth

-51.60%

EBITDA Margin

-11.50%

Operating Cashflow

-$7m

Free Cash Flow Return

-7.00%

ROIC

-10.10%

Interest Coverage

-16.20

Quick Ratio

6.40

Other Data

Shares on Issue (Fully Dilluted)

345m

HALO Sector

Healthcare

Next Company Report Date

20-May-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

NZD

Short Sell (% of issue)

0.14

ARX Announcements

Latest Announcements

Date Announcements

01 May 25

Initial substantial shareholding from AEF

×

Initial substantial shareholding from AEF

29 April 25

March 2025 Quarterly Report and Appendix 4C

×

March 2025 Quarterly Report and Appendix 4C

29 April 25

Investor Presentation

×

Investor Presentation

22 April 25

Notification of Quarterly Results Webinar

×

Notification of Quarterly Results Webinar

14 April 25

Notification of cessation of securities - ARX

×

Notification of cessation of securities - ARX

29 January 25

December 2024 Quarterly Report and Appendix 4C

×

December 2024 Quarterly Report and Appendix 4C

29 January 25

Investor Presentation

×

Investor Presentation

22 January 25

Notification of Quarterly Results Webinar

×

Notification of Quarterly Results Webinar

07 January 25

Notification regarding unquoted securities - ARX

×

Notification regarding unquoted securities - ARX

06 January 25

Aroa Incentive Plan

×

Aroa Incentive Plan

23 December 24

ARX First Clinical Evidence from MASTRR Study Published

×

ARX First Clinical Evidence from MASTRR Study Published

26 November 24

Appendix 4D and Half Year Report

×

Appendix 4D and Half Year Report

26 November 24

Aroa Biosurgery Half Yearly Results H1 FY25

×

Aroa Biosurgery Half Yearly Results H1 FY25

26 November 24

Aroa Half Year Results Presentation

×

Aroa Half Year Results Presentation

19 November 24

Notification of Half Year Results Webinar

×

Notification of Half Year Results Webinar

22 October 24

September 2024 Quarterly Report and Appendix 4C

×

September 2024 Quarterly Report and Appendix 4C

22 October 24

Investor Presentation

×

Investor Presentation

15 October 24

Notification of Quarterly Results Webinar

×

Notification of Quarterly Results Webinar

11 October 24

Notification of cessation of securities - ARX

×

Notification of cessation of securities - ARX

04 October 24

Change of Director's Interest Notice - CM

×

Change of Director's Interest Notice - CM

27 August 24

Change in substantial holding

×

Change in substantial holding

26 August 24

Change in substantial holding

×

Change in substantial holding

23 August 24

Notification regarding unquoted securities - ARX

×

Notification regarding unquoted securities - ARX

23 August 24

Application for quotation of securities - ARX

×

Application for quotation of securities - ARX

23 August 24

Application for quotation of securities - ARX

×

Application for quotation of securities - ARX

ARX Fundamentals

Per Share Records

Historical data

Forecast data

NZD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.00 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.00 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 61.7 95.5 -2,721.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 673.0 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 71.8 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 0.02 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 82.5 793.4 -110.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.7 -2.5 -5.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.29 0.30 0.28 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.24 0.25 0.22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 80.9 1.1 -11.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 342 343 344 Lock Lock Lock
Basic m Lock Lock Lock Lock 342 343 344 Lock Lock Lock

Financial Records

Historical data

Forecast data

NZD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 40 63 69 Lock Lock Lock
     Growth % Lock Lock Lock Lock 77.6 59.7 9.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 39 58 71 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 30 53 59 Lock Lock Lock
     Growth % Lock Lock Lock Lock 100.3 75.3 11.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock 76.1 83.5 85.4 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 24 16 15 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -1 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.0 82.0 -690.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -14.1 -1.6 -11.5 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 3 4 4 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -5 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.2 44.3 -154.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -22.0 -7.7 -17.9 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 0 -12 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 0 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 56.3 95.3 -2,583.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -21.1 -0.6 -15.4 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -12 -4 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 5 8 7 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -35 7 10 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 38 -1 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -16 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -154.7 38.7 -11.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.4 -0.2 -0.2 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 57 46 30 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 113 117 111 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 5 7 6 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -52 -39 -23 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 12 15 16 Lock Lock Lock
Equity $m Lock Lock Lock Lock 99 104 94 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 106 108 101 Lock Lock Lock
     Growth % Lock Lock Lock Lock 64.8 2.5 -6.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -7.4 -0.3 -9.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -8.5 -0.4 -11.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -9.8 -4.4 -11.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -10.1 -0.4 -10.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -13.8 -3.4 -7.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

NZD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -4.9 -2.7 -16.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 9.2 38.8 2.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -52.2 -37.4 -24.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 11.9 9.9 7.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 11.3 9.3 6.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 71.9 59.0 43.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -171.7 -47.7 -77.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 3.3 2.9 2.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.6 2.3 1.6 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.6 0.9 1.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 3.3 3.1 2.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.5 0.6 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.5 0.6 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -20.8 -0.6 -17.5 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -7.3 -0.3 -10.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -7.4 -0.3 -9.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -8.5 -0.4 -11.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -8.5 -0.4 -11.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 142.8 157.1 232.6 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 110.0 126.3 144.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 252.9 283.4 376.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 37.5 53.2 49.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 215.4 230.2 326.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.14%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ARX Shortsell

Frequently Asked Questions

The current share price of Aroa Biosurgery Ltd (ARX:ASX) is AU$0.45.
The 52-week high share price for Aroa Biosurgery Ltd (ARX:ASX) is AU$0.81.
The 52-week low share price for Aroa Biosurgery Ltd (ARX:ASX)? is AU$0.35.
The current TTM dividend payout for Aroa Biosurgery Ltd (ARX:ASX) is 0.00.
Aroa Biosurgery Ltd (ARX:ASX) does not pay a dividend.
Aroa Biosurgery Ltd (ARX:ASX) has a franking level of 0.0%.
Aroa Biosurgery Ltd (ARX:ASX) is classified in the Healthcare.
The current P/E ratio for Aroa Biosurgery Ltd (ARX:ASX) is 673.00.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.